louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02964832: Assessment of Chest Compression Depth Obtained Using the Smartphone Application as an Educational Tool With New Attachment Device
Official title: Assessment of Chest Compression Depth Obtained Using the Smartphone Application as an Educational Tool With New Attachment Device
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Basic Cardiac Life Support
Keywords: Basic Cardiac Life Support, Education, Feedback
Lead sponsor: Soonchunhyang University Hospital
Sponsor class: OTHER
First posted: 2016-11-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: To improve the quality of CPR education, we want to assess the validity and reliability of the feedback depth measured by smartphone applications according to the smartphone attachment sites as an educational tool. However, in the prior study, armband method showed overestimated chest compression depth. The reason of the overestimation was analyzed that the weight of the smartphone amplified the inertial force to produce additional linear movement. In this study, we will make new device to fix the smartphone on the arm and on the hand and compare the chest compression depth between CPR manikin and smartphone application.


Eligibility criteria: Inclusion Criteria:

* BLS provider or instructor

Exclusion Criteria:

* one who has physical problem in chest compression

Primary outcomes:
measure: Assessment of validity of Chest compression depth by smartphone application,PocketCPR
timeFrame: Through study completion, average 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00961532: Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Official title: Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Intracerebral Hemorrhage
Keywords: intracerebral hemorrhage
platelets
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: Northwestern Memorial Hospital
First posted: 2009-08-19
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.


Eligibility criteria: Inclusion Criteria:

* Spontaneous intracerebral hemorrhage as documented by head CT scan
* Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria:

* International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
* History of von Willebrand disease
* Pregnancy
* Known hypersensitivity to DDAVP or desmopressin
* Active cardiovascular disease or unstable angina
* Hyponatremia or history of hyponatremia
* Current or historical deep venous thrombosis or pulmonary embolism

Primary outcomes:
measure: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment
timeFrame: 60 minutes after treatment start
Secondary outcomes:
measure: Adverse Events : New Fever >=100.4F, Respiratory Distress or Pulmonary Edema on Chest Radiography, Rash, Hypotension (Systolic BP < 100 mm Hg or New Vasopressor Use or Increase in Vasopressor Dose by >25%)
timeFrame: within 6 hours of study treatment
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern Memorial Hospital
state: Illinois
Study officials:
affiliation: Northwestern University
name: Andrew M Naidech, MD MSPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Naidech AM, Maas MB, Levasseur-Franklin KE, Liotta EM, Guth JC, Berman M, Rosenow JM, Lindholm PF, Bendok BR, Prabhakaran S, Bernstein RA, Kwaan HC. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke. 2014 Aug;45(8):2451-3. doi: 10.1161/STROKEAHA.114.006061. Epub 2014 Jul 8.
Clinical trial NCT01378832: Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery
Official title: Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Infection in Elective Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Surgical Site Infection
Keywords: Intra-abdominal abscess
wound infection
colorectal surgery
Lead sponsor: Universidad Miguel Hernandez de Elche
Sponsor class: OTHER
First posted: 2011-06-22
Enrollment: 102
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Intrabdominal antibiotic irrigation will reduce wound and intrabdominal infection.

Detailed description: A prospective, randomized study was performed between January and December 2010. Patient inclusion criteria were a diagnosis of colorectal neoplasms and plans to undergo an elective curative surgery. Patients were divided into 2 groups: Group 1 (intra-abdominal irrigation with normal saline) and Group 2 (intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin). The occurrence of wound infections and intra-abdominal abscesses were investigated. Following the anastomosis, a microbiological sample of the peritoneal surface was obtained (sample 1). A second sample was collected following an irrigation with normal saline (sample 2). Finally, the peritoneal cavity was irrigated with a gentamicin-clindamycin solution and a third sample was obtained (sample 3).

Eligibility criteria: Inclusion Criteria:

* diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims.

Exclusion Criteria:

* preoperative diagnosis of chronic renal failure, because of the risk of nephrotoxicity associated with intraperitoneal gentamicin absorption
* an anastomotic leak in the postoperative course

Primary outcomes:
measure: Surgical site infection
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Ruiz-Tovar J, Santos J, Arroyo A, Llavero C, Armananzas L, Lopez-Delgado A, Frangi A, Alcaide MJ, Candela F, Calpena R. Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery. J Am Coll Surg. 2012 Feb;214(2):202-7. doi: 10.1016/j.jamcollsurg.2011.10.014.
Clinical trial NCT00129532: Trial of SAVVY and HIV in Ghana
Official title: Randomized Controlled Trial of SAVVY and HIV in Ghana
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: HIV Infections
Keywords: HIV transmission
Lead sponsor: Biosyn
Sponsor class: INDUSTRY
Collaborators: name: FHI 360
name: United States Agency for International Development (USAID)
First posted: 2005-08-12
Enrollment: 2142
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Detailed description: Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Eligibility criteria: Inclusion Criteria:

* 18 to 35 year old women
* HIV negative
* More than one sexual partner in past 3 months
* Average of 3 coital acts per week
* Willing to use vaginal gel and condoms for 12 months

Exclusion Criteria:

* HIV positive
* Pregnant

Primary outcomes:
measure: combined incidence of HIV-1 and HIV-2
Secondary outcomes:
Other outcomes:
Locations:
city: Accra
country: Ghana
facility: Noguchi Memorial Institute for Medical Research/University of Ghana
city: Kumasi
country: Ghana
facility: Komfo Anokye Teaching Hospital/Kwame Nkrumah University of Science and Technology
Study officials:
affiliation: FHI 360
name: Leigh Peterson, PhD
role: STUDY_CHAIR
References:
citation: Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R, Dorflinger L. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007 Dec 19;2(12):e1312. doi: 10.1371/journal.pone.0001312.
Clinical trial NCT03791632: Oral Health Among Children
Official title: Oral Health Knowledge and Practice Among 8-9 Years Old Children.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schoolboy
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2019-01-02
Enrollment: 240
Sex: ALL
Minimum age (years): 7
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1. Test group
2. Classes with a classical lecture style presentation
3. classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
4. classes with digital media intervention
Primary purpose: OTHER

Brief summary: The aim of this study is to identify the knowledge and behavior on dental health and hygiene among adolescents. In most cases, the investigators know tooth decay can be prevented and reversed at an early stage by observing good oral hygiene. Few studies have been done among adolescents.

This study could justify the implementation of public health actions in terms of prevention.


Eligibility criteria: Inclusion criteria:

- All children of classrooms selectionned

Exclusion criteria:

- Children absent on the day of the intervention

Primary outcomes:
measure: comparison of children's notes before and after a prevention intervention
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
measure: Compare the evolution of children's grades according to the type of intervention
timeFrame: before and after the explanation as well as one month and 6 months after the intervention
measure: Determine the timeframe by which children forget the information they have been given
timeFrame: before and after the explanation as well as one month and 6 months after the intervention
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Camille INQUIMBERT, PhD student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02192632: Dermatologists' Educational Demonstration for Epiduo Application
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Facial Acne
Local Adverse Effects
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-07-17
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and tolerability of this combination gel compared with BPO monotherapy in Korean patients, and test clinical practicability of dermatologists' educational demonstration for how to apply this gel in reducing uncomfortable irritations.


Eligibility criteria: Inclusion Criteria:

* mild to moderate acne were evaluated by Leeds revised acne grade from 2 to 6
* age: 18-40

Exclusion Criteria:

* pregnancy
* mental illness
* intake of oral isotretinoin within 6 months
* application of the other oral or topical acne medications
* chemical peeling or light based treatments within 6 weeks.

Primary outcomes:
measure: Percentile reduction of non-inflammatory & inflammatory acne lesions
timeFrame: 12 weeks
Secondary outcomes:
measure: Total number of local irriation effect counts (erythema, scaling, dryness, itching)
timeFrame: 12 week
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Dermatology, Seoul National University
state: Joungro
Study officials:
References:
Clinical trial NCT06972732: A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Official title: A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Study to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Type 2 Diabetes
Keywords: type 2 diabetes
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2025-05-15
Enrollment: 204
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.


Eligibility criteria: Inclusion Criteria:

* Has voluntarily agreed to participate in this clinical trial.
* Adults over 19 years of age
* Diagnosed with type 2 diabetes

Exclusion Criteria:

* Has severe renal and liver disorders
* Has type 1 diabetes
* Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study
* Those who are deemed ineligible to participate in the study by the investigator

Primary outcomes:
measure: HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)
timeFrame: From baseline to end of treatment at 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
state: Seocho District
Study officials:
References:
Clinical trial NCT06693232: Mobile Micro-learning on Nurses' Self-confidence, Motivation, and Stress
Official title: The Effect of Mobile Micro-learning on Critical Care Nurses' Self-confidence, Motivation, and Stress After Cardiopulmonary Resuscitation
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cardiopulmonary Arrest
Nurse's Role
Lead sponsor: Damanhour University
Sponsor class: OTHER
First posted: 2024-11-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: One group will receive mobile micro-learning.
Primary purpose: OTHER

Brief summary: Before and after effect of using mobile micro-learning on their self-confidence, motivation, and stress toward cardiopulmonary resuscitation.

Detailed description: This study aims to determine the effect of mobile micro-learning on critical care nurses' self-confidence, motivation, and stress after cardiopulmonary resuscitation.

The current study will use three scales. Self-Confidence Scale, Cardiopulmonary Motivation Scale, and Post-Code Stress Scale.

Mobile micro-learning is used easily to access video-based learning tips for effective practice for cardiopulmonary resuscitation.

Eligibility criteria: Inclusion Criteria:

* Critical care nurses who have worked in the intensive care unit for more than one year.

Exclusion Criteria:

* Critical care nurses who have less than one year of experience.

Primary outcomes:
measure: Self-Confidence Scale
timeFrame: before and after intervention immediately, after two week and after one month
measure: Cardiopulmonary motivation
timeFrame: before and after intervention immediately, after two week and after one month
measure: Post-Code Stress Scale
timeFrame: before and after intervention immediately, after two week and after one month
Secondary outcomes:
Other outcomes:
Locations:
city: Damanhūr
country: Egypt
facility: Faculty of nursing
state: Capital City Of Beheira Governorate
city: Damanhūr
country: Egypt
facility: Faculty of nursing Damanhour university
Study officials:
References:
citation: Zarshenas L, Mehrabi M, Karamdar L, Keshavarzi MH, Keshtkaran Z. The effect of micro-learning on learning and self-efficacy of nursing students: an interventional study. BMC Med Educ. 2022 Sep 7;22(1):664. doi: 10.1186/s12909-022-03726-8.
citation: Can S, Durgun H, Dalcali BK. Effect of online communication skills training on effective communication and self-efficacy and self-regulated learning skills of nursing students: A randomized controlled study. Nurse Educ Pract. 2022 Aug;63:103371. doi: 10.1016/j.nepr.2022.103371. Epub 2022 May 25.
Clinical trial NCT04576832: Mindfulness Training for Senior Leaders
Official title: Mindfulness Training for U.S. Army Senior Leaders
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cognitive Change
Keywords: mindfulness training
psychological health
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
First posted: 2020-10-06
Enrollment: 91
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The overarching goal of the project is to investigate if a mindfulness-based attention training (MBAT) program contextualized for Military Senior Leaders (SLs) might benefit SLs in three key domains: (1) cognitive abilities, (2) psychological well-being and self-reported physical health, and (3) strategic leadership skills and ability. The MBAT-SL program will be tested by the training cohorts and compared to the wait-list control cohorts who will receive the training after a no-training interval.


Eligibility criteria: Inclusion Criteria:

1. Individuals who are between 18 and 65 years of age.
2. Individuals who are fluent English speakers.
3. Individuals who are active-duty service members
4. Individuals who are willing and able to consent to participate in the study.
5. Individuals who participated in the courses provided by the Army War College (AWC).

Exclusion Criteria:

1. Individuals who have been hospitalized for psychological/mental health issues within the last month

Primary outcomes:
measure: Change in Sustained attention to response task (SART) score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
Secondary outcomes:
measure: Change in 5FMQ scores
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in Decentering score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in PANAS positive affect score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in PANAS negative affect score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in PSS score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in PHQ4 scores
timeFrame: Baseline (T1) to post-4-week training interval (T2).
Other outcomes:
measure: Change in Leadership Questionnaire
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in Anger score
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Change in Marital Satisfaction
timeFrame: Baseline (T1) to post-4-week training interval (T2).
measure: Applied Mindfulness Practice
timeFrame: Post-4-week training interval 1 (T2) and post-4-week training interval 2 (T3).
Locations:
city: Coral Gables
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Amishi Jha
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00913432: Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis
Official title: A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open Label, Uncontrolled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of AB1010 at 3 and 6 mg/kg/Day in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including Anti TNF Alpha if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Anti TNF Alpha
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Keywords: rheumatoid arthritis
methotrexate
DMARD
c-kit inhibitor
Lead sponsor: AB Science
Sponsor class: INDUSTRY
First posted: 2009-06-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard treatments.


Eligibility criteria: Inclusion Criteria:

1. Disease duration of at least 6 months Meet American College of Rheumatology (ACR) criteria for RA.
2. ACR functional class I-III
3. Have active RA
4. Failed (defined as active RA with stable dose during 3 months) i. methotrexate or ii. any DMARD including anti TNF alpha if patients previously failed methotrexate or iii. methotrexate in combination with any DMARD including anti TNF alpha

Exclusion Criteria:

1. Patient had a major surgery within 2 weeks prior to study entry.
2. Life expectancy \< 6 months.

Primary outcomes:
measure: American College of Rheumatology Score 50
timeFrame: week 12
Secondary outcomes:
measure: DAS28
timeFrame: week 4, 8 and 12
Other outcomes:
Locations:
Study officials:
affiliation: CHU de Lyon Sud
name: Jacques Tebib, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00683332: Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
Official title: A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Complicated Skin and Skin Structure Infections
Complicated Intra-abdominal Infections
Keywords: Observational study
Tigecycline
infection
skin
abdominal
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-05-23
Enrollment: 621
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who receive one dose of tigecycline

Brief summary: The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Detailed description: Three-thousand or 10% of total number of patients given tigecycline will be included in the study

Eligibility criteria: Inclusion Criteria:

* All patients from the study center who received or will receive at least one dose of Tygacil according to the approved product indication.

Exclusion Criteria:

* Previously discontinued Tygacil therapy due to significant safety concern.

Primary outcomes:
measure: Number of Participants With Spontaneous Adverse Events
timeFrame: 30 days post injection up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Manila
country: Philippines
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: